CHARM Therapeutics’ Post

The Precede Biosciences team and I have really appreciated the partnership and the investment from the team at Illumina Ventures. Wouter Meuleman and team, thank you for helping to make our mission to impact therapeutic decision-making a reality. If you want to learn more about Precede Biosciences, click on the link below to read the spotlight article 👇🏾. #aacr #oncology #healthcare #precisionmedicine #biology

I would love to see more people improve their health with this. Matomo.myalovea.com Acemannan is being integrated into high levels of medical research! Dr. Renee Hirte has been supervising the research of the plant extract, Acemannan, and says it has exceeded expectations. The goal of this research project is to validate the integrative support it can provide our monoclonal antibody therapy to achieve the best patient outcomes. Additionally, Ron Bruno, Board Director of Netwell Healthshare, says that "Alovéa’s proprietary Acemannan product IMMUN, is the most scientifically-validated technology we were able to find for achieving [our] goals." Acemannan is revolutionizing health, and we're lucky enough to share its benefits with the world. #dailyhealthyhabits #optimizeyourhealth #autoimmunesupport

Did you catch the latest issue of Drug Discovery World? In this insightful issue, Megan Thomas sat down with leading figures in the drug discovery field to explore the hottest trends and most promising areas for investment in 2024. From the potential of artificial intelligence to the growing importance of personalized medicine, there's no shortage of exciting developments on the horizon. But what are the biggest challenges facing the industry? And how can we overcome them to bring life-saving drugs to patients faster? Josh Ludwig, Global Director, Commercial Operations at ScaleReady, weighs in on the conversation on pages 8-9 here: https://lnkd.in/d5AAYUpu #cellandgenetherapy #CGT #healthinnovation #medtech

Washington University launches translational DiviTum® TKa trial: BettER! This study seeks to evaluate the impact of early therapeutic switching based on biomarker-driven insights, utilizing DiviTum TKa to guide treatment decisions. Read the full Press release: https://loom.ly/ay43Vvg "We are thrilled to once again collaborate with Washington University on another trial. This time it is a translational trial, which if successful would pave the way for increased uptake of DiviTum TKa, for the benefit of patients," said Anders Rylander, CEO of Biovica. #PrecisionMedicine #clinicaltrials #biomarkers #bcsm #investors #biovicb

Our SPATIALPlex Solutions bring innovative approaches to your biomarker and clinical development programs. Spatially visualizing drug activity with unparalleled precision, Flagship Biosciences supports discovery and target engagement decisions that transcend conventional approaches and enable vivid insights to refine drug efficacy. Learn more… https://hubs.la/Q02rq17H0 #SpatialBiology #SpatialPlexSolutions #DigitalPathology #DrugDevelopment

Follow to learn more about our biomarker strategies!

With #BIO2024 taking place this week in San Diego, the life sciences community closes in on a mid-year check-in point. A time when thousands of the greatest scientific innovators from across the globe come together to take a pulse on the state of the industry, reflect on the first half of the year and predict what lies ahead. As the life sciences community comes together and looks ahead to what's needed to accelerate the development and delivery of modern therapeutics, they must move beyond traditional research spaces and large-scale manufacturing and global distribution centers. In my recent interview with @BioPharmaDive, I discuss how SmartLabs is helping to bridge the gap between traditional and modern drug development through our first-in-class, integrated offerings which combine reconfigurable lab infrastructure, operations, and scientific expertise. Read the full Q&A on BioPharmDive: https://lnkd.in/g_iYzUXe #SmartLabs #EnablingTheFutureOfScience #BioPharma #LabSolutions

Biomarker discovery and development is not only a powerful tool for developing better and more personalized #diagnostics, but is also an effective way to de-risk your future #drugdevelopment activities. And, thanks to advances in #omics technologies, the possibilities for profiling biological molecules across different states and conditions has been truly revolutionized - advancing data-driven biomarker #RandD. But how to make sense of these vast stores of omics #data in a way that is accessible to scientists and clinicians? For some hints, check out our white paper on #data driven biomarker R&D 👀👉https://lnkd.in/eaSJypGG

🌟 Exciting Growth in the Global Near Infrared Imaging Market! 🌟 The Global Near Infrared (NIR) Imaging Market is set to expand at a robust growth rate of 7-8% over the next five years. Explore more market insights and trends with our detailed analysis: https://lnkd.in/dUuxhuzy Key players shaping the NIR landscape include Thermo Fisher Scientific, Merck KGaA, Darmstadt, Germany, Agilent Technologies, CRISPR Therapeutics, GenScript, Lonza, PerkinElmer, Caribou Biosciences, Hera BioLabs, and OriGene. As we look ahead, the future of NIR imaging is bright, promising improved patient outcomes and revolutionary advancements in medical imaging. 🌐🔬 #NearInfraredImaging #MedicalImaging #HealthcareInnovation #NIRTechnology #ChronicDiseaseManagement #SurgicalAdvancements #HealthcareGrowth #MedicalResearch #FutureOfImaging #HealthcareTech #MedicalTechnology #HealthcareIndustry #ImagingTechnology #NIRImaging #SurgicalInnovation #AdvancedImaging #MedicalDevices #TechInHealthcare #HealthcareResearch #GlobalHealth #MedicalAdvancements #HealthcareSolutions #InnovationInHealthcare #ChronicDiseaseCare #MedicalTechTrends #HealthcareMarket #NIRImagingGrowth #RegulatorySupport #SurgicalProcedures #ImagingSolutions

PlexusDx is a proud member of the American Pharmacogenomics Association (APGxA)! APGxA is a pivotal organization in the field of pharmacogenomics, dedicated to advancing the scientific understanding and application of how genetic makeup influences drug response. As a central hub for professionals, APGxA drives education, research, and collaboration to integrate pharmacogenomics into clinical practice. By joining APGxA, PlexusDx reaffirms its commitment to improving patient care through personalized, effective, and safer drug therapies tailored to individual genetic profiles. We are excited to contribute to and benefit from the collective expertise and initiatives spearheaded by APGxA. Together, we aim to bridge the gap between genomic science and everyday healthcare, ensuring that personalized medicine becomes the standard for patient care. #Pharmacogenomics #APGxA #PersonalizedMedicine #PlexusDx #PrecisionHealth #HealthcareInnovation #GeneticTesting #PatientCare #MedicalResearch #ProfessionalDevelopment